REDX inhibitor provides multiple opportunities for cancer associated fibrosis 11-May-2023 By Liza Laws Data from the company’s lead fibrosis asset called RXC700 has highlighted multiple opportunities for patients with pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC).